Keros halts hypertension treatment trial on safety issues
15/01/2025 11:36
Jan 15 (Reuters) - Keros Therapeutics KROS.O said on Wednesday it would voluntarily halt testing of its experimental hypertension treatment due to safety concerns during a mid-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Keros Therapeutics
See all newsBrief: Keros Therapeutics May Offer Up To $350 Million Of Securities - SEC Filing
Keros Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Keros Therapeutics Q2 net loss narrows on lower expenses
Brief: Keros Therapeutics - Keith Regnante Resigns As CFO
Keros Therapeutics posts Q1 net loss as license revenue drops